Intrathecal immune reset in multiple sclerosis: Exploring a new concept

Medical Hypotheses

Volumn 82, Issue 3, 2014, Pages 300-309

  Bonnan, Mickael ^a  

^a Hospital F Mitterrand   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS, SPINAL; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 84893971675     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.12.015     Document Type: Article

References (156)

1. Meinl E., Krumbholz M., Derfuss T., Junker A., Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci 2008, 274:42-44.
2. Fox R.J., Thompson A., Baker D., et al. Setting a research agenda for progressive multiple sclerosis: the international collaborative on progressive MS. Multiple Scler 2012, 18:1534-1540.
3. De Stefano N., Giorgio A., Battaglini M., et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010, 74:1868-1876.
4. Kalkers N.F., Ameziane N., Bot J.C., Minneboo A., Polman C.H., Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002, 59:1572-1576.
5. Coles A.J., Twyman C.L., Arnold D.L., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
6. Inglese M., Mancardi G.L., Pagani E., et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004, 75:643-644.
7. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
8. Rocca M.A., Mondria T., Valsasina P., et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 2007, 28:1659-1661.
9. Lucchinetti C.F., Popescu B.F., Bunyan R.F., et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011, 365:2188-2197.
10. Reynolds R., Roncaroli F., Nicholas R., Radotra B., Gveric D., Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 2011, 122:155-170.
11. Popescu B.F., Lucchinetti C.F. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012, 12:11.
12. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011, 24:224-229.
13. Geurts J.J. Is progressive multiple sclerosis a gray matter disease?. Ann Neurol 2008, 64:230-232.
14. Bø L., Vedeler C.A., Nyland H., Trapp B.D., Mørk S.J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Multiple Scler (Houndmills, Basingstoke, England) 2003, 9:323-331.
15. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
16. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
17. Kutzelnigg A., Faber-Rod J.C., Bauer J., et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007, 17:38-44.
18. Geurts J.J., Bo L., Roosendaal S.D., et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007, 66:819-827.
19. Bø L., Vedeler C.A., Nyland H.I., Trapp B.D., Mørk S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003, 62:723-732.
20. Magliozzi R., Howell O., Vora A., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
21. Howell O.W., Reeves C.A., Nicholas R., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
22. Antulov R., Carone D.A., Bruce J., et al. Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. J Neuroimaging 2011, 21:210-218.
23. Bo L., Geurts J.J., van der Valk P., Polman C., Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 2007, 64:76-80.
24. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123(Pt. 6):1174-1183.
25. Calabrese M., Poretto V., Favaretto A., et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012, 135:2952-2961.
26. Fisniku L.K., Chard D.T., Jackson J.S., et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008, 64:247-254.
27. De Stefano N., Matthews P.M., Filippi M., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003, 60:1157-1162.
28. Giorgio A., De Stefano N. Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spectroscopy. Neurol Sci 2010, 31:S245-S248.
29. Villar L.M., Masterman T., Casanova B., et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009, 211:101-104.
30. Walsh M.J., Tourtellotte W.W. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986, 163:41-53.
31. Yu X., Burgoon M., Green M., et al. Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time. J Neuroimmunol 2011, 240-241:129-136.
32. Colombo M., Dono M., Gazzola P., Chiorazzi N., Mancardi G., Ferrarini M. Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. Eur J Immunol 2003, 33:3433-3438.
33. Owens G.P., Ritchie A.M., Burgoon M.P., Williamson R.A., Corboy J.R., Gilden D.H. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003, 171:2725-2733.
34. Cortese I., Capone S., Luchetti S., Grimaldi L.M., Nicosia A., Cortese R. CSF-enriched antibodies do not share specificities among MS patients. Multiple Scler 1998, 4:118-123.
35. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Multiple Scler 1998, 4:111-117.
36. Derfuss T., Gurkov R., Then Bergh F., et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001, 124:1325-1335.
37. Confavreux C., Chapuis-Cellier C., Arnaud P., Robert O., Aimard G., Devic M. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psychiatry 1986, 49:1308-1312.
38. Tourtellotte W.W., Baumhefner R.W., Syndulko K., et al. The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching. J Neuroimmunol 1988, 20:217-227.
39. Trotter J.L., Garvey W.F. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 1980, 30:702-708.
40. Tourtellotte W.W., Baumhefner R.W., Potvin A.R., et al. Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids. Neurology 1980, 30:1155-1162.
41. Rudick R.A., Cookfair D.L., Simonian N.A., et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The multiple sclerosis collaborative research group. J Neuroimmunol 1999, 93:8-14.
42. Wilkerson L.D., Lisak R.P., Zweiman B., Silberberg D.H. Antimyelin antibody in multiple sclerosis: no change during immunosuppression. J Neurol Neurosurg Psychiatry 1977, 40:872-875.
43. Stüve O., Leussink V.I., Fröhlich R., et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009, 66:259-261.
44. Petereit H.F., Moeller-Hartmann W., Reske D., Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008, 117:399-403.
45. Piccio L., Naismith R.T., Trinkaus K., et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010, 67:707-714.
46. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.-A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006, 180:63-70.
47. Perry J.S., Han S., Xu Q., et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012, 4. p. 145ra106.
48. Tintore M., Rovira A., Rio J., et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083.
49. Masjuan J., Alvarez-Cermeno J.C., Garcia-Barragan N., et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006, 66:576-578.
50. Boscá I., Magraner M.J., Coret F., et al. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J Neuroimmunol 2010, 226:143-146.
51. Puel J., Gayet C., Averous S., Brochier B. Synthèse intrathécale des anticorps viraux au cours des encéphalits virales. Méd Mal Infect 1982, 10:616-619.
52. Villar L.M., Sadaba M.C., Roldan E., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
53. Tumani H., Tourtellotte W.W., Peter J.B., Felgenhauer K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The optic neuritis study group. J Neurol Sci 1998, 155:44-49.
54. Avasarala J.R., Cross A.H., Trotter J.L. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001, 58:2044-2045.
55. Durante L., Zaaraoui W., Rico A., et al. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Multiple Scler 2012, 18:587-591.
56. Perini P., Ranzato F., Calabrese M., Battistin L., Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006, 77:953-955.
57. Villar L.M., Masjuan J., Gonzalez-Porque P., et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002, 58:824-826.
58. Greve B., Magnusson C.G., Melms A., Weissert R. Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis. J Neuroimmunol 2001, 121:120-125.
59. Rinker J.R., Trinkaus K., Cross A.H. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006, 67:1288-1290.
60. Villar L.M., Masjuan J., González-Porqué P., et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003, 53:222-226.
61. Garcia-Barragan N., Villar L.M., Espino M., Sadaba M.C., Gonzalez-Porque P., Alvarez-Cermeno J.C. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol 2009, 16:380-385.
62. Bosca I., Villar L.M., Coret F., et al. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Multiple Scler (Houndmills, Basingstoke, England) 2010, 16:810-815.
63. Thangarajh M., Gomez-Rial J., Hedstrom A.K., et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Multiple Scler 2008, 14:1208-1213.
64. Beltrán E., Hernández A., Lafuente E.M., et al. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis. J Neuroimmunol 2012, 247:63-69.
65. Magraner M.J., Bosca I., Simó-Castelló M., et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012, 54:5-12.
66. Sena A., Rosado P., Ferret-Sena V., Coimbra J., Schuller E., Sindic C.J. Multiple sclerosis and intrathecal IgA synthesis. Acta Neurol Belg 1997, 97:36-38.
67. Lolli F., Halawa I., Link H. Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple sclerosis and controls. Acta Neurol Scand 1989, 80:238-247.
68. Goffette S., Schluep M., Henry H., Duprez T., Sindic C.J. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry 2004, 75:308-310.
69. Qin Y., Duquette P., Zhang Y., et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 2003, 83:1081-1088.
70. Harp C., Lee J., Lambracht-Washington D., et al. Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. J Neuroimmunol 2007, 183:189-199.
71. Siritho S., Freedman M.S. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009, 279:21-25.
72. Zeman A.Z., Kidd D., McLean B.N., et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 60:27-30.
73. Rojas J.I., Tizio S., Patrucco L., Cristiano E. Oligoclonal bands in multiple sclerosis patients: worse prognosis?. Neurol Res 2012, 34:889-892.
74. Lechner-Scott J., Spencer B., de Malmanche T., et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Scler 2012, 18:974-982.
75. Annunziata P., Giorgio A., De Santi L., et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci 2006, 244:97-102.
76. Joseph F.G., Hirst C.L., Pickersgill T.P., Ben-Shlomo Y., Robertson N.P., Scolding N.J. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009, 80:292-296.
77. Elliott C., Lindner M., Arthur A., et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012, 135:1819-1833.
78. Breij E.C.W., Brink B.P., Veerhuis R., et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008, 63:16-25.
79. Zhang Y., Da R.-R., Hilgenberg L.G., et al. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J Neuroimmunol 2005, 167:120-130.
80. Sadaba M.C., Tzartos J., Paino C., et al. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 2012, 247:86-94.
81. Zhou D., Srivastava R., Nessler S., et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:19057-19062.
82. von Budingen H.C., Harrer M.D., Kuenzle S., Meier M., Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008, 38:2014-2023.
83. Zhang Y., Da R.-R., Guo W., et al. Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis. J Clin Immunol 2005, 25:254-264.
84. Pandey S., Alcaro M.C., Scrima M., et al. Designed glucopeptides mimetics of myelin protein epitopes as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis. J Med Chem 2012, 55:10437-10447.
85. Linington C., Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1987, 17:61-69.
86. Rosenbluth J., Schiff R., Liang W.-L., Dou W. Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J Neurocytol 2003, 32:265-276.
87. Guseo A., Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975, 211:51-60.
88. Jankoovic B., Rakic I., Janjic M., Ivanus J., Mitrovic K. Effect of experimental allergic encephalomyelitis gamma-globulin upon the electrical activity of the brain. Experientia 1966, 22:459-460.
89. Bornstein M.B., Crain S.M. Functional studies of cultured brain tissues as related to "Demyelinative Disorders". Science 1965, 148:1242-1244.
90. Mehta P.D. Quantitation of IgG subclasses in cerebrospinal fluid of patients with multiple sclerosis. Ann N Y Acad Sci 1988, 540:261-263.
91. Di Pauli F., Gredler V., Kuenz B., et al. Features of intrathecal immunoglobulins in patients with multiple sclerosis. J Neurol Sci 2010, 288:147-150.
92. Bennett J.L., Haubold K., Ritchie A.M., et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol 2008, 199:126-132.
93. Colombo M., Dono M., Gazzola P., et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000, 164:2782-2789.
94. von Budingen H.C., Kuo T.C., Sirota M., et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 2012, 122:4533-4543.
95. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006, 59:880-892.
96. Franciotta D., Di Stefano A.L., Jarius S., et al. Cerebrospinal BAFF and Epstein-Barr virus-specific oligoclonal bands in multiple sclerosis and other inflammatory demyelinating neurological diseases. J Neuroimmunol 2011, 230:160-163.
97. Krumbholz M., Theil D., Derfuss T., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
98. Brettschneider J., Czerwoniak A., Senel M., et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PloS One 2010, 5:e11986.
99. Rupprecht T.A., Plate A., Adam M., et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflamm 2009, 6:42.
100. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol (Zurich, Switzerland) 2004, 14:164-174.
101. Corcione A., Casazza S., Ferretti E., et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004, 101:11064-11069.
102. Rupprecht T.A., Pfister H.W., Angele B., Kastenbauer S., Wilske B., Koedel U. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005, 65:448-450.
103. Sellebjerg F., Bornsen L., Khademi M., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
104. Frischer J.M., Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
105. Choi S.R., Howell O.W., Carassiti D., et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135:2925-2937.
106. Magliozzi R., Howell O.W., Reeves C., et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010, 68:477-493.
107. Chaitanya G.V., Omura S., Sato F., et al. Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflamm 2013, 10:125.
108. Junker A., Ivanidze J., Malotka J., et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130:2789-2799.
109. Skulina C., Schmidt S., Dornmair K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004, 101:2428-2433.
110. Lovato L., Willis S.N., Rodig S.J., et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011, 134:534-541.
111. Knopf P.M., Harling-Berg C.J., Cserr H.F., et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. Journal Immunol (Baltimore, Md.: 1950) 1998, 161:692-701.
112. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005, 11:335-339.
113. Lisak R.P., Benjamins J.A., Nedelkoska L., et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 2012, 246:85-95.
114. Steelman A.J., Li J. Poly(I:C) promotes TNFalpha/TNFR1-dependent oligodendrocyte death in mixed glial cultures. J Neuroinflamm 2011, 8:89.
115. Butinx M., Moreels M., Vandenabeele F., et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFNg and TNFa on apoptosis. J Neurosci Res 2004, 76:834-845.
116. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
117. Kuerten S., Schickel A., Kerkloh C., et al. Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response. Acta Neuropathol 2012, 124:861-873.
118. Tourtellotte W.W., Murthy K., Brandes D., Jurkowitz J., Fleming J.O. Immunosuppressive therapy of multiple sclerosis: I. Further studies with X-irradiation of central nervous system. Neurology 1975, 25:362-363.
119. Baumhefner R.W., Booe M.M., Tourtellotte W.W. Modulation of de novo CNS IgG synthesis with preservation of oligoclonal IgG in multiple sclerosis. Neurology 1979, 29:549.
120. Massaro A.R. Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids. J Neurol 1978, 219:221-226.
121. Elsner W., Tourtellotte W.W., Murthy K., Booe M.M., Potvin A., Syndulko K. Multiple sclerosis: effect of dexamethasone on in situ central nervous system IgG synthesis. Neurology 1978, 403.
122. Openshaw H., Lund B.T., Kashyap A., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000, 6:563-575.
123. Fassas A., Passweg J.R., Anagnostopoulos A., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002, 249:1088-1097.
124. Samijn J.P., te Boekhorst P.A., Mondria T., et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006, 77:46-50.
125. Lu J.-Q., Joseph J.T., Nash R.A., et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch Neurol 2010, 67:716-722.
126. Metz I., Lucchinetti C.F., Openshaw H., et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007, 130:1254-1262.
127. Lu S.J. JContinued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009, 66:116-120.
128. Saiz A., Carreras E., Berenguer J., et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001, 56:1084-1089.
129. Mondria T., Lamers C.H.J., te Boekhorst P.A.W., Gratama J.W., Hintzen R.Q. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:1013-1015.
130. Stüve O., Marra C.M., Jerome K.R., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747.
131. Martin M., Cravens P.D., Winger R., et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008, 65:1596-1603.
132. Harrer A., Tumani H., Niendorf S., et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Multiple Scler 2013, 19:1209-1212.
133. Kowarik M.C., Pellkofer H.L., Cepok S., et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011, 76:1214-1221.
134. Monson N.L., Cravens P.D., Frohman E.M., Hawker K., Racke M.K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005, 62:258-264.
135. Harjunpaa A., Wiklund T., Collan J., et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001, 42:731-738.
136. Stüve O., Cepok S., Elias B., et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005, 62:1620-1623.
137. Hawker K., O'Connor P., Freedman M.S., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-471.
138. Rubenstein J.L., Fridlyand J., Abrey L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350-1356.
139. Thaunat O., Patey N., Gautreau C., et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008, 85:1648-1653.
140. Kavanaugh A., Rosengren S., Lee S.J., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008, 67:402-408.
141. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
142. DiLillo D.J., Hamaguchi Y., Ueda Y., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008, 180:361-371.
143. Withers D.R., Fiorini C., Fischer R.T., Ettinger R., Lipsky P.E., Grammer A.C. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 2007, 109:4856-4864.
144. von Budingen H.C., Bar-Or A., Zamvil S.S. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011, 23:713-720.
145. Rieselbach R.E., Di Chiro G., Freireich E.J., Rall D.P. Subarachnoid distribution of drugs after lumbar injection. N Engl J Med 1962, 267:1273-1278.
146. de Andres C., Teijeiro R., Alonso B., et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One 2012, 7:e34103.
147. Storek J., Zhao Z., Lin E., et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). Clin Immunol 2004, 113:285-298.
148. Gomez A.M., Willcox N., Molenaar P.C., et al. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. Ann N Y Acad Sci 2012, 1274:48-59.
149. Chen C.I., Masih-Khan E., Jiang H., et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 2013, 162:483-488.
150. de Weers M., Tai Y.T., van der Veer M.S., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011, 186:1840-1848.
151. Atanackovic D., Panse J., Hildebrandt Y., et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 2011, 96:1512-1520.
152. Lin W.Y., Gong Q., Seshasayee D., et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 2007, 110:3959-3967.
153. Winter O., Dame C., Jundt F., Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 2012, 189:5105-5111.
154. DeBoy C.A., Rus H., Tegla C., et al. FLT-3 expression and function on microglia in multiple sclerosis. Exp Mol Pathol 2010, 89:109-116.
155. Whartenby K.A., Calabresi P.A., McCadden E., et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005, 102:16741-16746.
156. Schwab N., Ulzheimer J.C., Fox R.J., et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology 2012, 78:458-467. discussion 465.